Addex TherapeuticsADXN
13F holders, Q2 2026 (June 30)2holders −2
1new positions
3sold out
$5.71avg. 13F price*
At the end of Q2 2026, 2 institutions reported holding Addex Therapeutics Ltd. (ADXN) in their 13F filings, down 2 from Q1 2026. 1 opened new positions and 3 sold out. The largest holders were UBS Group AG ($268) and SBI Securities Co., Ltd. ($6).
- Company
- Addex Therapeutics Ltd.
- CUSIP
- 00654J206
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $268 |
| Exits | 3 | $3K |
All 13F filers, Q1 2026 → Q2 2026: 47 shares bought and 454 shares sold, net −407 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| UBS Group AG | 0.00% | New | 47 | $268 |
| SBI Securities Co., Ltd. | 0.00% | No change | 1 | $6 |
"% of holder's portfolio" is ADXN's weight in each manager's 13F, not the share of Addex Therapeutics Ltd. the manager owns.